Skip to main content
Fig. 5 | BMC Neurology

Fig. 5

From: Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers

Fig. 5

Effects of each CGRP mAb on MMDs. Temporal profiles of MMDs in patients treated with galcanezumab (n = 31, A), fremanezumab (n = 24, B), and erenumab (n = 13, C). Data are shown as mean ± SD. Statistical analysis was performed using one-way ANOVA with Dunnett’s post hoc test for galcanezumab and the Kruskal–Wallis test with Dunn’s post hoc test for fremanezumab and erenumab. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. D Overlay line graph depicting the temporal profiles of each CGRP mAb

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us